From: The potential use of mesenchymal stem cells and their exosomes in Parkinson’s disease treatment
Action and target cell | Investigators | Year and location | Estimated enrollment | Purpose | Status | Trial phase | Clinical Trials ID |
---|---|---|---|---|---|---|---|
Intravenous administration of autologous bone marrow derived MSCs | Yang Xiao Li Li | 2011 Guangzhou General Hospital of Guangzhou Military Command | 20 | Safety and efficacy | Unknown | Phase 1/2 | NCT01446614 |
Intra-arterial administration of autologous bone marrow derived MSCs in progressive supranuclear palsy | Rosaria Giordano | 2012 Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | 25 | Safety and efficacy | Unknown | Phase 1/2 | NCT01824121 |
Intra-arterial and intravenous administration of autologous adipose-derived SVF cells | Sharon McQuillan | 2014 Ageless Regenerative Institute | 0 | Safety and efficacy | Recruiting participants | Not Applicable | NCT01453803 |
Autologous adipose-derived SVF cells. Route of administration not defined | StemGenex | 2014 StemGenex San Diego | 75 | Safety and efficacy | Unknown | NCT02184546 | |
Intravenous administration of allogeneic bone marrow-derived MSCs | Mya Schiess | 2017 The University of Texas Health Science Center, Houston | 20 | Safety, feasibility, and efficacy | Recruitment completed | Phase 1 | NCT02611167 |
Intravenous administration of Umbilical Cord Derived MSCs | Xiqing Chai | 2018 Hebei Newtherapy BIo-Pharma Technology Co., Ltd | 20 | Safety and efficacy | Enrolling by invitation | Phase 1 | NCT03550183 |
Intrathecal and Intravenous administration of umbilical cord derived MSCs | Abdallah Awidi | 2018 University of Jordan | 10 | Short term and long term safety | Recruiting | Phase 1/2 | NCT03684122 |
Infusion of allogeneic bone marrow-derived MSCs | Mya C Schiess | 2020 The University of Texas Health Science Center, Houston | 45 | Safety and efficacy | Not yet recruiting | Phase 2 | NCT04506073 |